Needham analyst Michael Matson has maintained their neutral stance on HOLX stock, giving a Hold rating on July 18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Hold rating due to a combination of factors including Hologic’s recent financial performance and future growth prospects. The company reported better-than-expected revenue and earnings per share for the third quarter of fiscal year 2025, and management has slightly increased their guidance for the full year. However, there are concerns about the company’s organic sales growth, which has slowed compared to previous quarters.
Additionally, Hologic’s gross and operating margins have declined year-over-year, indicating potential challenges in maintaining profitability. Although the company anticipates a recovery in growth and aims to achieve mid-single digit revenue growth in fiscal year 2026, the path to recovery is uncertain. Given that Hologic’s expected earnings per share growth may fall behind its peers, Matson has opted to maintain a Hold rating on the stock.
In another report released on July 18, Bank of America Securities also maintained a Hold rating on the stock with a $70.00 price target.